Fennec Pharmaceuticals Inc (FENC)
0 followers · Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Rostislav C. Raykov |
| Employees: | 10 |
| Web site: | fennecpharma.com |
| PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709 (919) 636-4530 | |
- Formally known as:
- Adherex Technologies Inc
- Adherex Technologies Inc
- Adherex Technologies, Inc. Ordinary
- FENNEC PHARMACEUTICALS, INC
| Date | Ratio |
|---|---|
| 2005-08-02 | 1:5 |
| 2011-08-30 | 1:18 |
| 2014-09-05 | 1:3 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Fennec Pharmaceuticals Inc. develops product candidates for use in the treatment of cancer in the U.S. Its lead product PEDMARK is a formulation of Sodium Thiosulfate that has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Please log in first to see chart